MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

115.17 +0.27 (+0.23%)
Official Closing Price Updated: 4:10 PM EDT, Jun 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
3 Dividend Stocks to Hold for the Long Haul ↗
They have a habit of consistently raising their payouts. 
Via The Motley Fool
Topics Intellectual Property
Discover which dow jones stocks are making waves on Monday. ↗
Via Chartmill
News headline image
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
From Merck & Co., Inc.
Via Business Wire
Stay informed with the top movers within the dow jones index on Friday. ↗
Via Chartmill
Top dow jones movers in Friday's session ↗
Via Chartmill
Explore the top gainers and losers within the dow jones index in today's session. ↗
Via Chartmill
Discover which dow jones stocks are making waves on Thursday. ↗
Via Chartmill
News headline image
Merck Animal Health to Acquire TARGAN
From Merck & Co., Inc.
Via Business Wire
Stay informed with the top movers within the dow jones index on Wednesday. ↗
Via Chartmill
News headline image
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
From Merck & Co., Inc.
Via Business Wire
Exploring the top movers within the dow jones index during today's session. ↗
Via Chartmill
Uncover the latest developments among dow jones stocks in today's session. ↗
Via Chartmill
News headline image
The Smartest Dividend ETF to Buy With $1,000 Right Now -- and It's Up 19% in 2026 ↗
This low-fee fund offers a glorious mix of growth and income. 
Via The Motley Fool
Topics ETFs Stocks
Friday's session: top gainers and losers in the dow jones index ↗
Via Chartmill
News headline image
Merck: Navigating the Patent Cliff and Future Growth Prospects ↗
Join us as we dissect Merck's stock potential and the challenges it faces with the impending patent cliff of Keytruda. Can this pharmaceutical giant maintain its edge in the market? 
Via The Motley Fool
Topics Intellectual Property
These dow jones stocks are moving in today's session ↗
Via Chartmill
Top dow jones movers in Thursday's session ↗
Via Chartmill
News headline image
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Year, According to Wall Street ↗
Wall Street analysts expect market-beating returns from healthcare and communication services stocks over the next year. 
Via The Motley Fool
Topics ETFs Intellectual Property Stocks
News headline image
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026 ↗
It is finally bouncing back after several challenging years. 
Via The Motley Fool
Top dow jones movers in Tuesday's session ↗
Via Chartmill
Uncover the latest developments among dow jones stocks in today's session. ↗
Via Chartmill
News headline image
Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
What's going on in today's session: dow jones movers ↗
Via Chartmill
Top dow jones movers in Monday's session ↗
Via Chartmill
News headline image
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
Via ACCESS Newswire
Explore the top gainers and losers within the dow jones index in today's session. ↗
Via Chartmill
News headline image
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
News headline image
VYM vs. SCHD: Which U.S. Dividend ETF Is a Better Buy? ↗
When choosing dividend ETFs, diversification is a top priority. 
Via The Motley Fool
Topics ETFs
News headline image
Merck to Participate in the Jefferies Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story